FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3012962068> ?p ?o ?g. }

• W3012962068 endingPage "02" @default.
• W3012962068 startingPage "OT3" @default.
• W3012962068 abstract "Abstract Background: The enumeration of circulating tumour cells (CTCs) using the FDA-cleared CellSearch system has repeatedly been proven to bear prognostic significance in patients with localized and metastatic breast cancer (MBC) (Bidard et al. Lancet Oncol 2014; Janni et al. CCR 2016). In addition, CTC count has been suggested to be a valuable alternative for physician-based decision making in choosing between hormone therapy and chemotherapy as frontline treatment for patients with estrogen receptor-positive, HER2-negative MBC (Bidard et al. SABCS 2018). Challenges for the implementation of CTCs as a biomarker or a source of liquid biopsy in clinical practice include that most isolation methods only detect a limited number of CTCs in a blood sample in a subset of patients, even in those with clinically proven metastatic disease, and the limited availability of comparative data on technical variability between different CTC detection assays. Methods: In this study, we compare CTC detection rates in paired 7.5 ml blood samples from patients with MBC starting a new line of treatment using two commercially available CTC detection assays. All patients are recruited at GZA Hospitals, campus Sint-Augustinus, Antwerp, Belgium. The first CTC detection system is the CellSearch system, currently the only FDA-cleared system for the enumeration of CTCs in patients with MBC. This system employs an immunomagnetic CTC enrichment based on the expression of Epithelial Cell Adhesion Molecule (EPCAM) followed by an immunofluorescent CTC detection based on the expression of cytokeratins (CK) in EPCAM+ enriched cells. With this system, only EPCAM/CK double positive cells can be qualified as CTCs. The second system is the Rarecytes system, an automated scanner for immunofluorescently stained cell smears of the entire buffy coat of blood samples. With this system, CTCs will be enriched and detected in a single-step measurement using a cocktail of anti-EPCAM and anti-CK fluorescently labeled antibodies, thereby allowing to detect also single-marker positive CTCs. Based on CTC detection prevalence data in patients with MBC that are available for the CellSearch system and a prespecified hypothesis that with both detection methods a discordant result (relative to a cut-off of &gt;= or &lt;5 CTCs/7.5 ml blood) will be measured in 25% of patients, we aim to include 100 patients with MBC in this benchmarking study in order to be able to detect at least a 15% difference in CTC detection rate in favor of one of both techniques with 80% power at a significance level of 0.05. Concordance/discordance of CTC results between both detection methods will be analyzed both as a dichotomized variable relative to different cut-off values using the McNemar test and Cohen’s kappa test and as a continuous variable using the intraclass correlation coefficient. Expected results and conclusions: Upon submission of the abstract, 30 patients with MBC have been included in this trial after an accrual period of 4 months. Full results are expected mid 2020. Detailed comparison of CTC detection rates between both techniques will not only render analytical data on the performance of the Rarecytes system compared to the CellSearch system - the current gold standard in the field - but might also shed light on the frequency of EPCAM/CK single-positive CTCs in patients with MBC. Conflicts of interest: This study is partially funded by a grant from Rarecyte, Inc. Contact details for collaboration: Dieter Peeters (HistoGeneX NV, Antwerp, Belgium): dieter.peeters@histogenex.com; Andy Buys (Translational Cancer Research Unit, Antwerp, Belgium): andy.buys@gza.be. Citation Format: Dieter Peeters, Andy Buys, Hannah Ledegen, Kathlyn Moehlig, Steffi Oeyen, Dieter Rondas, Alexia De Beukelaer, Steven Van Laere, Liesbet Vervoort, Peter Vermeulen, Christopher Ung, Mark Kockx, Luc Dirix. A comparative study of two detection platforms of circulating tumour cells in patients with metastatic breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr OT3-18-02." @default.
• W3012962068 created "2020-04-03" @default.
• W3012962068 creator A5002579049 @default.
• W3012962068 creator A5006499239 @default.
• W3012962068 creator A5006708502 @default.
• W3012962068 creator A5020647566 @default.
• W3012962068 creator A5022173747 @default.
• W3012962068 creator A5045078504 @default.
• W3012962068 creator A5050123381 @default.
• W3012962068 creator A5062602932 @default.
• W3012962068 creator A5073639522 @default.
• W3012962068 creator A5077531941 @default.
• W3012962068 creator A5080379723 @default.
• W3012962068 creator A5082207346 @default.
• W3012962068 creator A5087519263 @default.
• W3012962068 date "2020-02-15" @default.
• W3012962068 modified "2023-09-30" @default.
• W3012962068 title "Abstract OT3-18-02: A comparative study of two detection platforms of circulating tumour cells in patients with metastatic breast cancer" @default.
• W3012962068 doi "https://doi.org/10.1158/1538-7445.sabcs19-ot3-18-02" @default.
• W3012962068 hasPublicationYear "2020" @default.
• W3012962068 type Work @default.
• W3012962068 sameAs 3012962068 @default.
• W3012962068 citedByCount "0" @default.
• W3012962068 crossrefType "journal-article" @default.
• W3012962068 hasAuthorship W3012962068A5002579049 @default.
• W3012962068 hasAuthorship W3012962068A5006499239 @default.
• W3012962068 hasAuthorship W3012962068A5006708502 @default.
• W3012962068 hasAuthorship W3012962068A5020647566 @default.
• W3012962068 hasAuthorship W3012962068A5022173747 @default.
• W3012962068 hasAuthorship W3012962068A5045078504 @default.
• W3012962068 hasAuthorship W3012962068A5050123381 @default.
• W3012962068 hasAuthorship W3012962068A5062602932 @default.
• W3012962068 hasAuthorship W3012962068A5073639522 @default.
• W3012962068 hasAuthorship W3012962068A5077531941 @default.
• W3012962068 hasAuthorship W3012962068A5080379723 @default.
• W3012962068 hasAuthorship W3012962068A5082207346 @default.
• W3012962068 hasAuthorship W3012962068A5087519263 @default.
• W3012962068 hasConcept C121608353 @default.
• W3012962068 hasConcept C126322002 @default.
• W3012962068 hasConcept C126894567 @default.
• W3012962068 hasConcept C138944611 @default.
• W3012962068 hasConcept C143998085 @default.
• W3012962068 hasConcept C2775930923 @default.
• W3012962068 hasConcept C2776677690 @default.
• W3012962068 hasConcept C2779013556 @default.
• W3012962068 hasConcept C2779529041 @default.
• W3012962068 hasConcept C530470458 @default.
• W3012962068 hasConcept C61238886 @default.
• W3012962068 hasConcept C71924100 @default.
• W3012962068 hasConceptScore W3012962068C121608353 @default.
• W3012962068 hasConceptScore W3012962068C126322002 @default.
• W3012962068 hasConceptScore W3012962068C126894567 @default.
• W3012962068 hasConceptScore W3012962068C138944611 @default.
• W3012962068 hasConceptScore W3012962068C143998085 @default.
• W3012962068 hasConceptScore W3012962068C2775930923 @default.
• W3012962068 hasConceptScore W3012962068C2776677690 @default.
• W3012962068 hasConceptScore W3012962068C2779013556 @default.
• W3012962068 hasConceptScore W3012962068C2779529041 @default.
• W3012962068 hasConceptScore W3012962068C530470458 @default.
• W3012962068 hasConceptScore W3012962068C61238886 @default.
• W3012962068 hasConceptScore W3012962068C71924100 @default.
• W3012962068 hasIssue "4_Supplement" @default.
• W3012962068 hasLocation W30129620681 @default.
• W3012962068 hasOpenAccess W3012962068 @default.
• W3012962068 hasPrimaryLocation W30129620681 @default.
• W3012962068 hasRelatedWork W2016753039 @default.
• W3012962068 hasRelatedWork W2395906155 @default.
• W3012962068 hasRelatedWork W2403224401 @default.
• W3012962068 hasRelatedWork W2740052915 @default.
• W3012962068 hasRelatedWork W3012962068 @default.
• W3012962068 hasRelatedWork W3028445690 @default.
• W3012962068 hasRelatedWork W3197299853 @default.
• W3012962068 hasRelatedWork W3209475169 @default.
• W3012962068 hasRelatedWork W4380150251 @default.
• W3012962068 hasRelatedWork W2006001742 @default.
• W3012962068 hasVolume "80" @default.
• W3012962068 isParatext "false" @default.
• W3012962068 isRetracted "false" @default.
• W3012962068 magId "3012962068" @default.
• W3012962068 workType "article" @default.